Syringe demonstrates cost benefits of sustainable design

Published: 3-Mar-2010
Packaging Drug Delivery Pharmaceutical

Cambridge Consultants unveils an innovative concept for prefilled syringes, cutting pack volume in half.

Cambridge Consultants has unveiled a novel "green" pre-filled syringe concept called Syreen for the self-administration of medicines.

Instead of glass, Syreen syringes are made from cyclic olefin polymer (COP) plastic, which means there is no need for secondary packaging. The company claims it is a first in this area of medical devices.

The makeup of the Syreen allows syringes to clip together, nesting in a pack, while the COP design doubles as the outer shell of the packaging itself. There is no need, therefore, for fillers such as cardboard and styrofoam, reducing the packaging weight by 30% and volume by 50% compared with standard packaging.

"This marriage of economy and ecology shows that medical device companies will likely see competitive benefits by taking sustainability seriously," said Phil Lever, commercial director, Drug Delivery Devices for pharma technology firm Cambridge Consultants, which has offices in Cambridge in the UK and US.

To use Syreen, the prefilled syringe is simply unclipped and put against the desired area on the skin. After delivery, with a simple snap, the user ejects the needle into the sharps bin, allowing the user to recycle the plastic capsule.

Patient safety is further increased because the COP plastic syringe features a curved surface over the needle that, while keeping the syringe from rolling and reducing needle-stick accidents, also ensures overall stability and depth control during injection. With separated plunger and stopper, the design also makes it impossible to take in blood or other contaminants, reducing the risk of cross infection.

Cambridge Consultants is currently seeking to develop the Syreen concept with large pharmaceutical and pharmaceutical packaging companies.

  • Companies:
  • Cambridge Consultants
See more

You may also like

Manufacturing

MIT spinout designs gentle process for billions of engineered cells in minutes

Read more
Kytopen has engaged Cambridge Consultants to co-develop the first Flowfect system using continuous fluid flow combined with electric fields

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. Likarda and VitalTE LifeSciences join forces to simplify HRT with hydrogel drug delivery technology Core-Shell Spherification (CSS) aims to optimise the HRT process by promoting the extended and consistent release of hormones such as testosterone and oestrogen
  4. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

MIT spinout designs gentle process for billions of engineered cells in minutes

Kytopen has engaged Cambridge Consultants to co-develop the first Flowfect system using continuous fluid flow combined with electric fields
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Synthetic biology: engineering the future

That synthetic biology will become the next big engineering discipline in the 21st century is clearly quite a claim. Is there any justification to support this statement?
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Aspirations for better pack design

As manufacturers look to provide treatments for the long-term management of increasingly complex diseases and medical conditions, Cambridge Consultants discusses the role of design in meeting the needs of an ageing population and the trend towards self-medication by patients at home
Drug Delivery

Cambridge Consultants teams up with Novartis and Owen Mumford

To develop auto-injector for MS patients
Drug Delivery

New inhaler delivers more drug to the deep lung

High performance, easy to use dry powder inhaler does not depend on breath intake strength
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Distribution

Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01

The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
Subscribe now